{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:08:22Z","timestamp":1790168902720,"version":"4.1.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>COVID-19 has proven to have a wide range of symptoms in human patients, prompting investigation into relevant biomarkers and underlying biological mechanisms. In this study, we aimed to develop a robust quantitative N-glycoproteomics approach for complex plasma samples and to characterize the altered glycosylation profiles associated with COVID-19 severity.<\/jats:p>\n                  <jats:p>We analyzed plasma samples from 16 survivors and 15 non-survivors, collected at three distinct time points following hospital admission. Using data-dependent acquisition (DDA) mass spectrometry, combined with a spectral library and the \u201cmatch-between-runs\u201d strategy, we profiled 397 unique glycopeptides and 62 glycan species, derived from 50 proteins across 86 glycosylation sites.<\/jats:p>\n                  <jats:p>By assessing both cross-sectional differences and longitudinal changes, we identified several site-specific glycosylation alterations that may serve as potential markers of disease severity. The most notable site-specific change was in the complement C1q A-chain (C1QA) at Asn146, with non-survivors having less fucosylation at hospital admission. We also observed increased bisection of immunoglobulins in non-survivors (IgG3\/4 Asn177 and IgM Asn146) and glycosylation pattern changes in acute-phase proteins. Longitudinally, the fucosylation levels of C1QA increased in the non-survivors, whereas they decreased in the survivors.<\/jats:p>\n                  <jats:p>These findings highlight the potential value of site-specific glycoproteomic profiling for improving the molecular understanding of COVID-19 severity.<\/jats:p>","DOI":"10.1093\/glycob\/cwag079","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:40:42Z","timestamp":1790077242000},"source":"Crossref","is-referenced-by-count":0,"title":["Temporal\n                    <i>N<\/i>\n                    -glycoproteomic differences between COVID-19 survivors and non-survivors at hospital admission and beyond"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4190-3460","authenticated-orcid":false,"given":"Xue","family":"Yu","sequence":"first","affiliation":[{"name":"Biomolecular Mass Spectrometry and Proteomics, Bijvoet Centre for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University , Utrecht ,","place":["The Netherlands"]},{"name":"Netherlands Proteomics Center , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Dingess","sequence":"additional","affiliation":[{"name":"Biomolecular Mass Spectrometry and Proteomics, Bijvoet Centre for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University , Utrecht ,","place":["The Netherlands"]},{"name":"Netherlands Proteomics Center , Utrecht ,","place":["The Netherlands"]},{"name":"Danone Global Research & Innovation , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-9711","authenticated-orcid":false,"given":"Rita","family":"Pavasini","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara , Ferrara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-188X","authenticated-orcid":false,"given":"Gianluca","family":"Campo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara , Ferrara ,","place":["Italy"]},{"name":"Maria Cecilia Hospital, GVM Care & Research , Cotignola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spadaro","family":"Savino","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara , Ferrara ,","place":["Italy"]},{"name":"Intensive Care Unit, Azienda Ospedaliero-Universitaria di Ferrara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J R","family":"Heck","sequence":"additional","affiliation":[{"name":"Biomolecular Mass Spectrometry and Proteomics, Bijvoet Centre for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University , Utrecht ,","place":["The Netherlands"]},{"name":"Netherlands Proteomics Center , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karli R","family":"Reiding","sequence":"additional","affiliation":[{"name":"Biomolecular Mass Spectrometry and Proteomics, Bijvoet Centre for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University , Utrecht ,","place":["The Netherlands"]},{"name":"Netherlands Proteomics Center , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,23]]},"container-title":["Glycobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/glycob\/advance-article-pdf\/doi\/10.1093\/glycob\/cwag079\/71344239\/cwag079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/glycob\/advance-article-pdf\/doi\/10.1093\/glycob\/cwag079\/71344239\/cwag079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:49:24Z","timestamp":1790167764000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/glycob\/advance-article\/doi\/10.1093\/glycob\/cwag079\/8832208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/glycob\/cwag079","relation":{},"ISSN":["1460-2423"],"issn-type":[{"value":"1460-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"cwag079"}}